<DOC>
	<DOCNO>NCT00457860</DOCNO>
	<brief_summary>RATIONALE : The CAT-8015 immunotoxin bind tumor cell kill without harm normal cell . This may effective treatment chronic lymphocytic leukemia ( CLL ) , prolymphocytic leukemia ( PLL ) , small lymphocytic lymphoma ( SLL respond chemotherapy , surgery radiation therapy . PURPOSE : Phase I dose escalation study determine maximum tolerate dose CAT-8015 immunotoxin treat patient chronic lymphocytic leukemia , prolymphocytic leukemia small lymphocytic lymphoma respond treatment</brief_summary>
	<brief_title>Safety Study CAT-8015 Immunotoxin Patients With CLL , PLL SLL With Advance Disease</brief_title>
	<detailed_description>OUTLINE : Patients receive CAT-8015 IV 30 minute day 1 , 3 , 5 follow rest . Treatment repeat every 4 week total 10 course absence dose limit toxicity , complete response disease progression . Patients follow 1 , 3 , 6,12,15,18 , 21 , 24 month follow start last treatment cycle . Cohorts 3-6 patient receive escalate dos recombinant CAT-8015 maximum tolerate dose ( MTD ) determine . The MTD define dose proceed 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , between16 25 new patient add MTD cohort depend well CAT-8015 tolerate .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Immunotoxins</mesh_term>
	<criteria>INCLUSION CRITERIA : DISEASE CHARACTERISTICS : Confirmed diagnosis Bcell leukemia ( CLL , PLL SLL ) Measurable disease Patients chronic lymphocytic leukemia ( CLL ) , small lymphocytic lymphoma ( SLL ) eligible fail 2 prior course standard chemotherapy and/or biologic therapy ( e.g . Rituxan ) treatment progressive disease medically indicate . Patients prolymphocytic leukemia ( PLL ) eligible fail least one prior standard chemotherapeutic regimen . Medical indication treatment include progressive diseaserelated symptom , progressive cytopenia due marrow involvement , progressive painful splenomegaly adenopathy , rapidly increase lymphocytosis , autoimmune hemolytic anemia thrombocytopenia increase frequency infection . PATIENT CHARACTERISTICS : Performance status ECOG 02 Life expectancy Life expectancy great 6 month , assess principal investigator Other Patients cancer meet eligibility criterion le 5 year diseasefree survival consider casebycase basis Ability understand sign inform consent Female male patient agree use approve method contraception study EXCLUSION CRITERIA : Documented ongoing central nervous system involvement malignant disease ( history CNS involvement exclusion criterion ) History bone marrow transplant Pregnant breastfeeding female Patients whose plasma contain either significant level antibody CAT8015 measure ELISA , antibody neutralizes bind CAT8015 CD22 measure competition ELISA . HIV positive serology ( due increase risk severe infection unknown interaction CAT8015 antiretroviral drug ) Hepatitis B surface antigen positive Uncontrolled , symptomatic , intercurrent illness include limited : infection require systemic antibiotic , congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness , social situation would limit compliance study requirement Hepatic function : serum transaminase ( either ALT AST ) direct bilirubin : ≥ Grade 2 , unless bilirun due Gilbert ’ disease Renal function : serum creatinine clearance ≤60mL/min estimate CockroftGault formula Hematologic function : The ANC &lt; 1000/cmm , platelet count &lt; 50,000/cmm , cytopenia judge investigator due underlying disease ( i.e . potentially reversible antineoplastic therapy ) Baseline coagulopathy &gt; grade 3 unless due anticoagulant therapy A patient exclude pancytopenia ≥ Grade 3 , erythropoietin dependence , due disease , base result bone marrow study Pulmonary function : Patients &lt; 50 % predict forced expiratory volume ( FEV1 ) &lt; 50 % predict diffusing capacity carbon monoxide ( DLCO ) , correct hemoglobin concentration alveolar volume . Note : Patients prior history pulmonary illness require PFTs . FEV1 assess follow bronchodilator therapy . Recent prior therapy : Cytotoxic chemotherapy , corticosteriods ( except stable dos prednisone ) , whole body electron beam radiation therapy , hormonal , biologic systemic therapy investigational therapy malignancy 3 week prior entry trial Less equal &lt; 3 month prior monoclonal antibody therapy ( i.e . rituximab ) Patients receive receive radiation therapy le 3 week prior study entry exclude providing volume bone marrow treat less 10 % also patient measurable disease outside radiation port</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>CLL</keyword>
	<keyword>PLL</keyword>
	<keyword>SLL</keyword>
	<keyword>Relapse</keyword>
	<keyword>Refractory</keyword>
	<keyword>immunotoxin</keyword>
	<keyword>HA22</keyword>
	<keyword>CAT-8015</keyword>
	<keyword>immunotherapy</keyword>
</DOC>